THE DAVIO 2 TRIAL:
Phase 2, Multicenter Study of DURAVYU™
všlifercept for Previously-Treated
Wet Age-Related Macular Degeneration

Carl D. Regillo, MD
Partner, Mid Atlantic Retina
Director Retina Service, Wills Eye Hospital
Professor of Ophthalmology, Thomas Jefferson University
Philadelphia, PA, USA

On behalf of the DAVIO 2 trial investigators

Presented at Clinical Trials at the Summit 2024, Park City, UT

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901.
DURAVYU™ is an investigational product; it has not been approved by the FDA. FDA approval and the
timeline for potential approval is uncertain.
Financial Disclosures

- **Consultant:** 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, Aviceda, Biocryst, Bausch and Lomb, Coherus, Cognition, EyePoint, Genentech, Iveric, Jcyte, Janssen, Kodiak, Kyoto Drug Development, Lineage, Merck, NGM, Neurotech, Novartis, Novelty Nobility, Ocugen, Ocuterra, Ocuphire, Opthea, Outlook, Ray, Regeneron, RegenXBio, Sandoz, Stealth, Thea, Zeiss, Zip Bio

- **Research grant support:** 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Gyroscope, Iveric, Janssen, Kodiak, Lineage, NGM, Notal, Novartis, Ocugen, Ocuterra, Opthea, Regeneron, RegenXBio
EYP-1901 (DURAVYU™): Vorolanib in Durasert E™

EYP-1901 combines a new mechanism for the treatment of VEGF-mediated ocular diseases with IVT bioerodible drug delivery using established technology.

Vorolanib
Potent, selective pan-VEGF receptor inhibitor

Durased E
Bioerodible, sustained IVT drug delivery

EYP-1901 insert at month 5 post-injection

3

**ANG**, angiopoietin; **FGF(R)**, fibroblast growth factor (receptor); **IVT**, intravitreal; **PDGF(R)**, platelet-derived growth factor (receptor); **PLGF**, placental growth factor; **TIE2**, tyrosine-protein kinase receptor TIE-2; **VEGF(R)**, vascular endothelial growth factor (receptor). DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU™ is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
DAVIO 2: Phase 2 trial of EYP-1901 vs aflibercept in previously-treated wet AMD

Primary endpoint
Combined mean change in BCVA at Weeks 28 and 32 (6 months after EYP-1901 injection)

Key Inclusion & Exclusion Criteria
- Diagnosed with wAMD at any time
- History of documented response to anti-VEGF
- History of ≥2 injections in last 6 months
- BCVA 85 to 35 letters (20/20 to 20/200)
- Excluded CST >350 µm, IRF >25 µm, RPED >400 µm

Criteria for Supplemental Injection
BCVA reduction ≥5 letters from best on-study measurement due to wAMD AND CST increase ≥75 µm from lowest on-study measurement
OR
BCVA reduction ≥10 letters from best on-study measurement due to wAMD
OR
CST increase ≥100 µm from lowest on-study measurement from 2 consecutive visits
OR
Presence of new or worsening vision-threatening hemorrhage due to wAMD

BCVA, best corrected visual acuity; CST, central subfield thickness; D, day; IRF, intraretinal fluid; q8W, every 8 weeks; RPED, retinal pigment epithelium detachment; VEGF, vascular endothelial growth factor; W, week; wAMD, wet age-related macular degeneration. Singh RP, et al. Presented at the Macula Society Annual Meeting 2024, Palm Springs, CA; February 7-10, 2024. DAVIO 2 Clinicaltrials.gov Identifier: NCT05381948.
DAVIO 2 baseline characteristics: Well-balanced across arms

<table>
<thead>
<tr>
<th>Baseline Characteristics (N = 156)</th>
<th>Aflibercept 2 mg q8W (n = 54)</th>
<th>EYP-1901 2 mg (n = 50)</th>
<th>EYP-1901 3 mg (n = 52)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years (range)</td>
<td>75.9 (52–93)</td>
<td>76.4 (61–93)</td>
<td>75.4 (56–89)</td>
</tr>
<tr>
<td>Female, %</td>
<td>53.7%</td>
<td>64.0%</td>
<td>67.3%</td>
</tr>
<tr>
<td>Mean BCVA, ETDRS letters (range)</td>
<td>73.4 (41–85) (~20/32)</td>
<td>73.9 (52–84) (~20/32)</td>
<td>74.9 (46–85) (~20/32)</td>
</tr>
<tr>
<td>Mean CST, μm (range)</td>
<td>265.7 (178–348)</td>
<td>267.0 (192–400)</td>
<td>262.9 (186–345)</td>
</tr>
<tr>
<td>Median length of time for wAMD diagnosis prior to screening, months (range)</td>
<td>28.1 (2.4–273.8)</td>
<td>24.3 (2.4–168.1)</td>
<td>28.1 (2.4–145.3)</td>
</tr>
<tr>
<td>Mean number of injections in the 12 months prior to screening (range)a</td>
<td>9.5 (2–12)</td>
<td>10.2 (2–13)</td>
<td>10.0 (2–13)</td>
</tr>
</tbody>
</table>

*Normalized values using topline Table 9-1. Other data are from topline Tables 2 and 3. BCVA, best-corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; q8W, every 8 weeks; VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration. Data on file; Singh RP, et al. Presented at the Macula Society Annual Meeting 2024, Palm Springs, CA; February 7–10, 2024. DAVIO 2 Clinicaltrials.gov Identifier: NCT05381948.
DAVIO 2 primary endpoint: EYP-1901 statistically non-inferior to aflibercept in maintaining BCVA over 32 weeks

Mean change in BCVA from baseline visit

-10 -5 0 5 10

Day 1 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week 28 Week 32

EY-1901 dosing

Predefined non-inferiority margin -4.5 letters

Aflibercept 2mg q8W (n = 53) +1.3
EYP-1901 2 mg (n = 48) +1.0
EYP-1901 3 mg (n = 52) +0.9

Mean change in BCVA vs aflibercept 2 mg q8W

DAVIO 2 INTERIM DATA NOV 2023: DATABASE LOCK PENDING

Data from topline Table 4-1. BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; q8W, every 8 weeks.

Secondary endpoint: Central Subfield Thickness was similar to aflibercept over 32 weeks with EYP-1901

Mean change in CST from baseline visit

EYP-1901 2 mg (n=48) +15.1
EYP-1901 3 mg (n=52) +10.6
Aflibercept 2 mg q8W (n=53) +5.4

Mean change in CST vs aflibercept 2 mg q8W +9.7 +5.2

Data from topline Table 6. CST, central subfield thickness; q8W, every 8 weeks.
Secondary endpoint: Central Subfield Thickness was similar to aflibercept over 32 weeks with EYP-1901

Mean change in CST from baseline visit

- EYP-1901 2 mg (n = 48) +15.1
- EYP-1901 3 mg (n = 52) +10.6
- Aflibercept 2 mg q8W (n = 53) +5.2

Mean change in CST vs aflibercept 2 mg q8W

Sawtooth pattern in CST apparent between injections in aflibercept q8W arm; not seen in EYP-1901 arms

Data from topline Table 6. CST, central subfield thickness; q8W, every 8 weeks.
≥64% of eyes receiving EYP-1901 were supplemental injection–free up to Week 32

≥83% of EYP-1901 eyes (n=102) received 0–1 supplemental injections during Weeks 8–32

EYP-1901–treated eyes receiving aflibercept supplementation, Weeks 8–32

Number of aflibercept supplemental injections

<table>
<thead>
<tr>
<th>Injection Count</th>
<th>EYP-1901 2 mg (n = 50)</th>
<th>EYP-1901 3 mg (n = 52)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>31 (62.0%)</td>
<td>32 (61.5%)</td>
</tr>
<tr>
<td>1</td>
<td>5 (10.0%)</td>
<td>5 (9.6%)</td>
</tr>
<tr>
<td>2</td>
<td>12 (24.0%)</td>
<td>11 (21.2%)</td>
</tr>
<tr>
<td>3</td>
<td>1 (2.0%)</td>
<td>3 (5.8%)</td>
</tr>
<tr>
<td>4</td>
<td>1 (1.9%)</td>
<td>5 (9.6%)</td>
</tr>
</tbody>
</table>

EYP-1901 2 mg reduced treatment burden by 89% compared to prior 6 months

*Injections in year prior to and during DAVIO 2 trial*

- EYP-1901 3 mg (n = 52)
- EYP-1901 2 mg (n = 50)


VEGF, vascular endothelial growth factor. DAVIO 2 Clinicaltrials.gov Identifier: NCT05381948.
EYP-1901 3 mg reduced treatment burden by 85% compared to prior 6 months

Injections in year prior to and during DAVIO 2 trial

- Anti-VEGF injection
- Aflibercept loading dose
- Aflibercept + EYP-1901
- No injection
- Missed visit
- Last visit
- Supplemental injection

Change in mean injections per 6 months

- EYP-1901 2 mg (n = 50) -89%
- EYP-1901 3 mg (n = 52) -85%

EYP-1901: Well-tolerated with an acceptable safety profile through Week 32 and no ocular SAEs related to EYP-1901

Key Ocular Findings

- No reported EYP-1901-related ocular SAEs
- Four ocular SAEs reported in a study eye – none deemed related to EYP-1901
- No reported EYP-1901-related systemic SAEs
- >97% of AEs reported were mild or moderate and generally expected with IVT injection
- No cases of:
  - Insert migration into the anterior chamber
  - Retinal occlusive vasculitis
- No discontinuations were related to EYP-1901 treatment

AE, adverse event; IVT, intravitreal; SAE, serious adverse event.

### Ocular AEs reported in ≥5% of study eyes

<table>
<thead>
<tr>
<th></th>
<th>Aflibercept 2 mg q8W (n = 54)</th>
<th>EYP-1901 2 mg (n = 53)</th>
<th>EYP-1901 3 mg (n = 53)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study eyes with AEs</td>
<td>20 (37.0)</td>
<td>30 (56.6)</td>
<td>29 (54.7)</td>
</tr>
<tr>
<td>Worsening wAMD</td>
<td>2 (3.7)</td>
<td>7 (13.2)</td>
<td>6 (11.3)</td>
</tr>
<tr>
<td>Conjunctival hemorrhage</td>
<td>2 (3.7)</td>
<td>6 (11.3)</td>
<td>3 (5.7)</td>
</tr>
<tr>
<td>Vitreous floaters</td>
<td>0 (0)</td>
<td>3 (5.7)</td>
<td>4 (7.5)</td>
</tr>
<tr>
<td>Retinal hemorrhage</td>
<td>1 (1.9)</td>
<td>1 (1.9)</td>
<td>5 (9.4)</td>
</tr>
<tr>
<td>Cataract</td>
<td>3 (5.6)</td>
<td>2 (3.8)</td>
<td>3 (5.7)</td>
</tr>
<tr>
<td>Eye pain</td>
<td>1 (1.9)</td>
<td>2 (3.8)</td>
<td>3 (5.7)</td>
</tr>
<tr>
<td>Vitreous detachment</td>
<td>2 (3.7)</td>
<td>3 (5.7)</td>
<td>2 (3.8)</td>
</tr>
<tr>
<td>Subretinal fluid</td>
<td>1 (1.9)</td>
<td>3 (5.7)</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

Data from topline Table 11-2. AE, adverse event; q8W, every 8 weeks; wAMD, wet age-related macular degeneration. Data on file; Singh RP, et al. Presented at the Macula Society Annual Meeting 2024, Palm Springs, CA; February 7-10, 2024. DAVIO 2 Clinicaltrials.gov Identifier: NCT05381948.
Summary: EYP-1901 Demonstrated Non-inferiority to Aflibercept with Stable BCVA and a Favorable Safety Profile while Reducing Treatment Burden vs Aflibercept in Eyes with wAMD

DAVIO 2: Largest IVT TKI trial to date
• Prospective, randomized, aflibercept-controlled phase 2 trial evaluating a single injection of EYP-1901

Primary end point
• BCVA: Statistically non-inferior change vs aflibercept; stable over 6 months

Favorable safety profile
• Most ocular AEs were expected with IVT injection; no EYP-1901–related ocular SAEs

Secondary end points
• Strong anatomical control: <10 µm CST difference vs aflibercept at 6 months
• ≥64% of eyes were supplemental injection–free up to 6 months
• ≥85% mean reduction in treatment burden vs prior 6 months

Phase 3 clinical program to start in H2 2024

AE, adverse event; BCVA, best corrected visual acuity; CST, central subfield thickness; IVT, intravitreal; SAE, serious adverse event; TKI, tyrosine kinase inhibitor; wAMD, wet age-related macular degeneration. DAVIO 2 Clinicaltrials.gov Identifier: NCT05381948.
Thank you to all investigators for support of the DAVIO 2 trial

- Neal Palejwala, Phoenix, AZ
- David Boyer, Beverly Hills, CA
- Vrinda Hershberger, Melbourne, FL
- Sunil Patel, Abilene, TX
- William Bridges, Asheville, NC
- Shilpa Gulati, Springfield, MA
- David Eichenbaum, Saint Petersburg, FL
- Philip Storey, Austin, TX
- Veeral Sheth, Lemont, IL
- Ashkan Abbey, Dallas, TX
- Darren Bell, San Antonio, TX
- Lindsey Harris, Houston, TX
- Joel Pearlman, Sacramento, CA
- Scott Friedman, Lakeland, FL
- Brandon Busbee, Nashville, TN
- Suk Jin Moon, Winter Haven, FL
- Payam Amini, Pasadena, CA
- Ivan Battle, Lenexa, KS
- Brian Berger, Austin, TX
- Eugene Chang, Redlands, CA
- Steven Charles, Germantown, TN
- Arshad Khanani, Reno, NV
- Nikolas London, Poway, CA
- David Warrow, Hagerstown, MD
- Charles Wykoff, The Woodlands, TX
- Hajir Dadgostar, Encino, CA
- Gregg Kokame, Aiea, HI
- Zachary Segal, Miami, FL
- Milan Shah, Carmel, IN
- Robert Stoltz, Marietta, GA
- Christina Flaxel, Portland, OR
- Thomas Aaberg, Grand Rapids, MI
- Jamin Brown, Liverpool, NY
- Paul Hahn, Teaneck, NJ
- John Kerrison, Charleston, SC
- Todd Schneiderman, Silverdale, WA
- Sam Mansour, Warrenton, VA
- John Davies, St Louis Park, MN
- Mitchell Goff, Salt Lake City, UT
- Brian Joondeph, Lakewood, CO
- Brett Rosenblatt, Hauppauge, NY
- Melvin Chen, Sarasota, FL
- Albert Edwards, Eugene, OR
- Philip Ferrone, Great Neck, NY
- Adam Gerstenblith, Hagerstown, MD
- Hani Salehi-Had, Huntington Beach, CA
- Pamela Weber, Shirley, NY
- Bradley Smith, Saint Louis, MO
- Kent Small, Glendale, CA
- Victor Gonzalez, McAllen, TX
- Dana Deupree, Clearwater, FL
- Lori Coors, Plano, TX
- Eric Suan, Baltimore, MD
- Ashkan Pirouz, Fullerton, CA
- Ivan Suner, Tampa, FL
- Jack Wells, West Columbia, SC
- Golnaz Javey, Lynchburg, VA
- John Thordsen, Wake Forest, NC
- Paulpoj Chiranand, Chicago, IL
- Baruch Kuppermann, Irvine, CA
- Amr Dessouki, Campbell, CA
- Serrhel Adams, Springdale, AR
- Allan Hunter, Springfield, OR
- Shailesh Gupta, Coral Springs, FL
- Sunil Gupta, Pensacola, FL
- Chirag Shah, Boston, MA
- Roger Goldberg, Walnut Creek, CA
- Jared Nielsen, West Des Moines, IA
- Alex Melamud, Fairfax, VA